Stabilised GHRH analog (codename for restricted compound)
Tesa
GHRH analog for visceral fat reduction and IGF-1 axis stimulation.
- Half-life~30 minutes plasma; effect via GH pulse amplification
- Dose range1 to 2 mg/day subcutaneous, evening · 12 to 26 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Binds GHRH receptors at the pituitary; amplifies endogenous GH pulse amplitude. Downstream IGF-1 elevation drives the body-composition effect.
Research
What the research shows.
Clinical research shows visceral adipose tissue reduction without subcutaneous fat loss, improved lipid profile, and modest IGF-1 elevation. Best-characterised GHRH analog in the research catalogue.
Tesa is the codename for a stabilised GHRH (growth-hormone-releasing hormone) analog. The compound has the most-developed clinical research base of any GHRH analog, with established dosing patterns from licensed-medicine use in HIV-associated lipodystrophy contexts.
Within the research-grade catalogue, dose patterns mirror the published trial protocols. Subcutaneous daily dosing in the evening aligns with the natural GH-pulse window during slow-wave sleep.
Contraindications
When not to use.
Active malignancy. Diabetic ketoacidosis. Severe insulin resistance. Pregnancy. Pediatric use without clinical oversight.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.